JM6 is a prodrug inhibitor of kynurenine 3-monooxygenase (KMO) that increases kynurenic acid levels and reduces extracellular glutamate in the brain. Metabolites in the kynurenine pathway, generated by tryptophan degradation, are thought to play an important role in neurodegenerative disorders, including Alzheimer's and Huntington's diseases. Chronic orally bioavailable administration of JM6 inhibits KMO in the blood, increasing kynurenic acid levels and reducing extracellular glutamate in the brain. JM6 prevents spatial memory deficits, anxiety-related behavior, and synaptic loss. JM6 also extends life span, prevents synaptic loss, and decreases microglial activation in a mouse model of Huntington's disease. References: Zhu Y, Zheng W, Ni H, Liu H, Xiao A, Cai H. Molecular cloning and characterization of a new and highly thermostable esterase from Geobacillus sp. JM6. J Basic Microbiol. 2015 Jul 15. doi: 10.1002/jobm.201500081. [Epub ahead of print] PubMed PMID: 26175347.

纯度：≥98%

CAS：1008119-83-2